Critical Medicines Act

Netherlands VWS Minister Confirms Structural Funding and Embedding of Pandemic Preparedness Programme

The Dutch government has committed €177 million annually to structurally embed pandemic preparedness into national health policy, focusing on surveillance, acute-care coordination, and medical countermeasure resilience. For life sciences and medical device sectors, this signals long-term investment in strategic stockpiling, supply chain resilience, and scalable production capacity for vaccines and diagnostics.

2 Apr 2026, 10:18zoek.officielebekendmakingen.nlNetherlands

European Commission Answer Outlines Availability Obligations for Gene Therapies and Links to Critical Medicines Act Proposal

The European Commission has signaled that upcoming pharmaceutical reforms and the Critical Medicines Act will introduce mandatory supply obligations and collaborative procurement for high-priority therapies. Companies face the risk of losing market protection if products are not made available within three years, necessitating a strategic review of EU-wide launch and distribution plans.

31 Mar 2026, 19:21europarl.europa.euEuropean Union

European Parliament Debates Urban Wastewater Directive EPR Costs and Medicine Supply Risks

The European Parliament is debating the implementation of the Urban Wastewater Treatment Directive’s EPR scheme, which shifts up to 100% of micropollutant treatment costs to pharmaceutical and cosmetic producers. Businesses face significant long-term financial liabilities and supply chain risks, necessitating close monitoring of national-level flexibilities that may mitigate costs for critical or low-margin products.

29 Mar 2026, 19:03europarl.europa.euEuropean Union

Norway Proposes Amendments to Pharmacy, Medicines and Medical Devices Laws to Implement EU Crisis Preparedness Regulations

Norway has proposed legislation to implement EU crisis preparedness and medical device supply regulations, mandating new reporting duties for market actors. Manufacturers and distributors must prepare for increased supply-chain transparency and the formal adoption of EUDAMED notification requirements in the Norwegian market.

29 Mar 2026, 05:58regjeringen.noNorwayEuropean Economic Area

EU Council Circulates Final Compromise Text for New Medicinal Products and EMA Regulation

The EU Council has finalized the compromise text for the new Pharmaceutical Regulation, consolidating the authorization and supervision framework for human medicines and advanced therapies. Marketing authorization holders must adapt to more stringent supply chain transparency requirements, mandatory shortage prevention plans, and a recalibrated system of market exclusivity incentives.

27 Mar 2026, 20:54data.consilium.europa.euEuropean Union

EU / France Commission Delivers Comments on Draft Decree on Medicinal Product Shortages (Notification 2025/0795/FR)

The European Commission has formally commented on France's draft decree to combat medicinal product shortages under the TRIS notification procedure. This intervention signals potential regulatory misalignment with EU single market rules, requiring pharmaceutical operators to monitor for changes in stockholding or supply obligations in the final French text.

27 Mar 2026, 11:57ec.europa.euEuropean UnionFrance

Estonia Appoints First Essential-Service Pharmacies and Wholesalers for Medicine Supply

Estonia has designated the first pharmacies and wholesalers as essential service providers (ETO), mandating strict crisis-response and supply continuity obligations starting February 2026. Impacted entities must align operations with new 48-hour restoration and 5-day autonomy standards, reflecting a broader regional trend toward mandatory pharmaceutical supply chain resilience.

26 Mar 2026, 11:44ravimiamet.eeEstonia

Estonian Agency of Medicines Announces 31 March Info Day for Marketing Authorisation Holders

The Estonian Agency of Medicines is hosting a March 2026 briefing for marketing authorisation holders on EU pharmaceutical law reforms and supply shortage management. Companies should use this session to align their compliance strategies with upcoming EU regulatory shifts and national procedural updates for medicinal products.

24 Mar 2026, 09:35ravimiamet.eeEstoniaEuropean Union

EU Member States Call for Environmental Permitting Omnibus to Accelerate Cross-Sector Permitting

Seven EU Member States are calling for a consolidated "environmental permitting omnibus" to harmonize fragmented project-approval rules across the energy, industrial, and biotech sectors. This push for regulatory simplification aims to reduce litigation risks and compliance costs for large-scale investments, while maintaining national control over specific permitting timelines.

18 Mar 2026, 16:27data.consilium.europa.euEuropean UnionBelgiumCzechiaFranceIrelandLatviaSlovakiaLuxembourg

Bulgaria Proposes Temporary Export Ban On Certain Medicinal Products (TRIS 2026/0122/BG)

Bulgaria has notified a draft order to temporarily ban the export of critical medicinal products, including insulins and SGLT-2 inhibitors, from March to May 2026. Manufacturers and distributors should anticipate localized supply chain restrictions as EU member states increasingly use emergency trade measures to address domestic medicine shortages.

17 Mar 2026, 19:54technical-regulation-information-system.ec.europa.euEuropean UnionBulgaria

EU Environment Council: Member States Call For Cross-sector Environmental Permitting Omnibus

EU Member States are calling for a consolidated 'environmental permitting omnibus' to harmonize fragmented permitting rules across major climate and industrial regulations. This initiative aims to reduce legal uncertainty and procedural delays for strategic projects, signaling a shift toward a more streamlined, cross-sectoral regulatory framework for industrial operations.

14 Mar 2026, 15:02data.consilium.europa.euEuropean Union

European Parliament Questions Commission on Urban Waste Water Treatment Directive and Medicine Supply Risks

European Parliament members have formally challenged the Commission on whether new wastewater treatment costs for pharmaceutical and cosmetic producers will undermine the security of medicine supplies. This political scrutiny signals potential flexibility or mitigation in how Member States implement Extended Producer Responsibility (EPR) fees to avoid compromising healthcare access.

14 Mar 2026, 07:44eur-lex.europa.euEuropean Union

EU Parliament Public Health Committee Draft Agenda: Votes on EU Pharmaceutical Package and European Biotech Act (18–19 March 2026)

The European Parliament's SANT Committee is scheduled to vote on the EU Pharmaceutical Package and review the European Biotech Act on March 18–19, 2026. This marks a critical step toward finalizing a comprehensive regulatory overhaul that will reshape market authorization, supply chain resilience, and safety standards for the life sciences sector.

13 Mar 2026, 10:50europarl.europa.euEuropean Union

EU Parliament SANT Committee To Review Negotiations on Critical Medicinal Products Proposal

The European Parliament is advancing negotiations on a new framework to secure the supply and availability of critical medicinal products. This signals increasing legislative momentum toward mandatory supply chain resilience and shortage mitigation requirements for pharmaceutical operators.

13 Mar 2026, 08:37europarl.europa.euEuropean Union

EU Council Prepares Trilogues on Critical Medicines Act Proposal

The EU has entered final negotiations on the Critical Medicines Act, moving toward a finalized framework for pharmaceutical supply security. Manufacturers should prepare for new non-price procurement criteria and potential obligations for strategic stockpiling and EU-based production capacity.

11 Mar 2026, 17:27eur-lex.europa.euEuropean Union

EU Council Four-Column Table on Critical Medicines Supply Framework Proposal

The EU Council has initiated trilogue negotiations on the Critical Medicines Act, signaling that final rules for securing the supply of essential pharmaceuticals are nearing completion. Pharmaceutical companies should prepare for new obligations regarding the availability and accessibility of critical medicines as the legislative framework moves toward formal adoption.

11 Mar 2026, 17:26consilium.europa.euEuropean Union

Medicines for Europe Urges EU Pharma Legislation to Safeguard Patient Access and Off‑Patent Medicines

Medicines for Europe is advocating for the rapid, digitalized implementation of EU pharmaceutical reforms and industrial acts to secure off-patent medicine supply chains. Companies should prepare for a more agile regulatory environment while monitoring the potential supply risks and cost burdens posed by the Urban Waste Water Treatment Directive.

4 Mar 2026, 16:03medicinesforeurope.comEuropean Union

EU Co-Legislators Reach Provisional Deal on Pharmaceutical Legislation Reform

EU co-legislators reached a provisional agreement on a major overhaul of pharmaceutical legislation, establishing new data protection timelines and supply chain security requirements. Businesses must prepare for adjusted market exclusivity periods, mandatory shortage prevention planning, and enhanced environmental risk assessments for antimicrobials.

28 Feb 2026, 12:41europarl.europa.euEuropean Union

EU Cyprus Council Presidency Sets Programme And Priority Files For Early 2026

The Cyprus EU Council Presidency has launched its H1 2026 agenda, prioritizing the Industrial Decarbonisation Accelerator Act and the Critical Medicines Act. Strategic planning should account for streamlined permitting for green industrial projects and enhanced supply chain security requirements for the pharmaceutical and biotech sectors.

26 Feb 2026, 10:04europarl.europa.euEuropean Union

European Parliament Debates Critical Medicines Act Proposal on Supply of Critical Medicinal Products (COM(2025)0102)

The European Parliament advanced the proposed Critical Medicines Act in January 2026, signaling a major legislative push to secure the EU’s pharmaceutical supply chain. Manufacturers should prepare for a shift toward EU-based production incentives, joint procurement criteria prioritizing resilience, and mandatory stockpiling requirements.

26 Feb 2026, 10:02europarl.europa.euEuropean Union